No Data
Green Bamboo Biology - B (02480) spent 0.4824 million Hong Kong dollars to repurchase 0.024 million shares on November 5th.
Green Bamboo Bio-B (02480) announced that on November 5, 2024, the company invested 0.4824 million...
LUZHU BIOTECH-B: SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2023
It is difficult to take a shortcut to 'ruisong,' and it is also difficult to support the commercialization of unique products. Green Bamboo Biology - B (02480) valuation.
For Lu Zhou Biotech, if shortcuts are not viable, they can only rely on their fundamental strengths to attract market attention. However, the core herpes zoster product has not yet been launched, and the company's future commercial prospects remain uncertain.
[Brokerage Focus] Guosen Securities maintains a rating of outperform on Green Bamboo Biotech (02480), indicating a favorable competitive landscape for domestic herpes zoster vaccine products.
Jinwu Finance News | Guosen Securities issued research guidance, Green Bamboo Biotech (02480) reported an adjusted loss of 0.11 billion yuan in the first half of 2024, compared to a loss of 0.079 billion yuan in the same period last year. In the first half of 2024, research and development expenses were 0.08 billion yuan (+142.4% year-on-year), mainly due to the Phase 3 clinical trial of LZ901 in China; administrative expenses were 0.045 billion yuan (+9.0% year-on-year), mainly due to increased depreciation of properties, factories, and equipment due to the completion of certain construction projects. The bank pointed out that LZ901, a candidate vaccine for herpes zoster, is one of the company's core pipelines and is expected to become the world's first.
LUZHU BIOTECH-B: Interim Report 2024
Luzhu Biotech -B (02480) released its interim performance, with a net loss of 0.11 billion yuan, a year-on-year increase of 38.5%
Green Bamboo Biology-B (02480) announced its six-month performance ending on June 30, 2024, with other income of 973...
No Data
No Data